Compare Novavax Inc (NVAX) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Standard Lithium Ltd — how do they compare? Novavax Inc trades at $8.03 (market cap $1.31B), while Standard Lithium Ltd trades at $2.44 (market cap $599.78M). The key difference: Novavax Inc is far larger — about 2.2× Standard Lithium Ltd's market cap, and Novavax Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| NVAX | SLI | |
|---|---|---|
Market Cap | $1.31B | $599.78M |
Sector | Health | Basic Materials |
52-Week High | $11.19 | $5.65 |
52-Week Low | $6.22 | $1.93 |
Enterprise Value | $890.95M | $462.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
SLI trades at $2.41, down 4.74% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported a net loss of $48.40M in 2025, with negative ROE and ROA, but beat EPS estimates in two recent quarters. Positive news includes a $225M DOE grant and progress on its South West Arkansas lithium project, with institutional buying from Amundi (64.9% stake increase in Q1 2026 per SEC filing).
The outlook hinges on project execution, as SLI transitions to production with strong analyst support (100% buy ratings). Key risks include cash burn from negative operating cash flow and reliance on financing, but de-risking milestones and government backing offer upside if timelines are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
